Bionano Net Income From Continuing Ops from 2010 to 2026
| BNGO Stock | USD 1.20 0.07 5.51% |
Net Loss | First Reported 2016-12-31 | Previous Quarter -6.9 M | Current Value -8.5 M | Quarterly Volatility 20.8 M |
Check Bionano Genomics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bionano Genomics' main balance sheet or income statement drivers, such as Tax Provision of 31.2 K, Interest Income of 1.5 M or Depreciation And Amortization of 17.2 M, as well as many indicators such as Price To Sales Ratio of 1.17, Dividend Yield of 0.0 or PTB Ratio of 1.02. Bionano financial statements analysis is a perfect complement when working with Bionano Genomics Valuation or Volatility modules.
Bionano | Net Income From Continuing Ops | Build AI portfolio with Bionano Stock |
Evaluating Bionano Genomics's Net Income From Continuing Ops across multiple reporting periods reveals the company's ability to sustain growth and manage resources effectively. This longitudinal analysis highlights inflection points, cyclical patterns, and structural changes that short-term snapshots might miss, offering deeper insight into Bionano Genomics's fundamental strength.
Latest Bionano Genomics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Bionano Genomics over the last few years. It is Bionano Genomics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bionano Genomics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Bionano Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (58,878,579) | |
| Coefficient Of Variation | (102.10) | |
| Mean Deviation | 47,404,811 | |
| Median | (23,365,364) | |
| Standard Deviation | 60,113,695 | |
| Sample Variance | 3613.7T | |
| Range | 214M | |
| R-Value | (0.73) | |
| Mean Square Error | 1779.3T | |
| R-Squared | 0.54 | |
| Significance | 0.0008 | |
| Slope | (8,734,737) | |
| Total Sum of Squares | 57818.5T |
Bionano Net Income From Continuing Ops History
About Bionano Genomics Financial Statements
Bionano Genomics investors utilize fundamental indicators, such as Net Income From Continuing Ops, to predict how Bionano Stock might perform in the future. Analyzing these trends over time helps investors make informed market timing decisions. For further insights, please visit our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Net Loss | -100.8 M | -105.9 M |
Pair Trading with Bionano Genomics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Bionano Genomics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Bionano Genomics will appreciate offsetting losses from the drop in the long position's value.Moving together with Bionano Stock
Moving against Bionano Stock
| 0.6 | ENS | Enersys Earnings Call This Week | PairCorr |
| 0.56 | APETF | Alpha Esports Tech | PairCorr |
| 0.55 | SLF | Sun Life Financial Earnings Call This Week | PairCorr |
| 0.51 | RCKY | Rocky Brands | PairCorr |
| 0.5 | YLLXF | Yellow Cake plc | PairCorr |
The ability to find closely correlated positions to Bionano Genomics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Bionano Genomics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Bionano Genomics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Bionano Genomics to buy it.
The correlation of Bionano Genomics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Bionano Genomics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Bionano Genomics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Bionano Genomics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out the analysis of Bionano Genomics Correlation against competitors. To learn how to invest in Bionano Stock, please use our How to Invest in Bionano Genomics guide.You can also try the Aroon Oscillator module to analyze current equity momentum using Aroon Oscillator and other momentum ratios.
Will Life Sciences Tools & Services sector continue expanding? Could Bionano diversify its offerings? Factors like these will boost the valuation of Bionano Genomics. Projected growth potential of Bionano fundamentally drives upward valuation adjustments. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Bionano Genomics data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Earnings Share (12.61) | Revenue Per Share | Quarterly Revenue Growth 0.213 | Return On Assets | Return On Equity |
Investors evaluate Bionano Genomics using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Bionano Genomics' intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Bionano Genomics' market price to deviate significantly from intrinsic value.
It's important to distinguish between Bionano Genomics' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Bionano Genomics should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Bionano Genomics' market price signifies the transaction level at which participants voluntarily complete trades.